Monopar Therapeutics shares are trading higher after the company announced it published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial." in the Hepatology Communications